OR HB2057

Prohibits health insurers and pharmacy benefit managers (PBMs) from requiring that reimbursement claims for prescription drugs include a modifier or indicator identifying the drug as a 340B drug

Establishes two exceptions to the prohibition: claims paid directly or indirectly by the state medical assistance program (Medicaid), and when a modifier is required by law to prevent duplicate discounts or rebates

Adds a statutory definition of "340B drug" as a covered drug subject to the federal pricing cap under 42 U.S.C. 256b(a)(1) that is dispensed at a 340B pharmacy

Amends three Oregon statutes: ORS 735.530, ORS 735.534, and ORS 743A.062

Takes effect on the 91st day following adjournment of the 2025 regular legislative session